172
Participants
Start Date
May 4, 2020
Primary Completion Date
December 21, 2022
Study Completion Date
December 21, 2022
ELX/TEZ/IVA
Fixed-dose combination (FDC) tablet for oral administration.
IVA
Tablet for oral administration.
The Prince Charles Hospital, Chermside
Institute for Respiratory Health, Nedlands
Telethon Kids Institute, Perth Children's Hospital, Nedlands
The Royal Children's Hospital, Parkville, VIC
Queensland Children's Hospital, South Brisbane
Universitair Ziekenhuis Gent, Ghent
Universitair Ziekenhuizen Leuven - Campus Gasthuisberg, Leuven
Charite Paediatric Pulmonology Department, Berlin
Universitaetsklinkum Koeln, CF-Studienzentrum, Cologne
Ruhrlandklinik Westdeutsches Lungenzentrum am Klinikum Essen, Essen
Universitatsklinikum Essen (AoR), Kinderklinik III, Abt. fur Pneumologie, Essen
Mukeviszidose-Zentrum am Universitatsklinikum Jena, Klinik fuer Kinder- und Jugendmedizin, Jena
Klinikum Innenstadt, University of Munich, München
Belfast City Hospital, Belfast
University Hospitals Birmingham NHS Foundation Trust, Birmingham
University Hospitals Bristol and Weston NHS Foundation Trust, Bristol Royal Hospital, Bristol
Royal Papworth Hospital NHS Foundation Trust, Cambridge
Western General Hospital, Edinburgh
Royal Devon and Exeter NHS Foundation Trust, Royal Devon and Exeter Hospital, Exeter
Clinical Research Facility, Queen Elizabeth University Hospital, Glasgow
Leeds General Infirmary, Leeds
St. James University Hospital, Leeds
Alder Hey Children's NHS Foundation Trust, Liverpool
Great Ormond Street Hospital for Sick Children, London
London and St Bartholomew's Hospital, London
The Newcastle upon Tyne Hospitals NHS Foundation Trust, The Royal Victoria Infirmary, Newcastle upon Tyne
Nottingham University Hospitals NHS Trust, Queens Medical Center, Nottingham
All Wales Adult Cystic Fibrosis Centre, University Hospital Llandough, Penarth
Southampton General Hospital, Southampton
Vertex Pharmaceuticals Incorporated
INDUSTRY